Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBIT (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBIT data on record, last reported at -$51.1 million in Q4 2025.

  • For Q4 2025, EBIT fell 152.45% year-over-year to -$51.1 million; the TTM value through Dec 2025 reached $55.4 million, up 234.17%, while the annual FY2025 figure was $55.4 million, 234.17% up from the prior year.
  • EBIT reached -$51.1 million in Q4 2025 per APLS's latest filing, down from $223.2 million in the prior quarter.
  • Across five years, EBIT topped out at $290.2 million in Q4 2021 and bottomed at -$194.3 million in Q2 2021.
  • Average EBIT over 5 years is -$62.7 million, with a median of -$102.5 million recorded in 2023.
  • Peak YoY movement for EBIT: crashed 156.53% in 2022, then skyrocketed 572.03% in 2025.
  • A 5-year view of EBIT shows it stood at $290.2 million in 2021, then plummeted by 156.53% to -$164.1 million in 2022, then surged by 48.48% to -$84.5 million in 2023, then skyrocketed by 215.37% to $97.5 million in 2024, then tumbled by 152.45% to -$51.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$51.1 million in Q4 2025, $223.2 million in Q3 2025, and -$33.3 million in Q2 2025.